DR-0201, a CD20-directed bispecific antibody, has demonstrated robust B-cell depletion in early clinical studies, showing ...

Under the terms of the deal, Sanofi will pay $600 million upfront to buy an affiliate of the California-based biotech, called ...

In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic ...

VCG. Shanghai is set to host a global investment promotion conference next week, bringing together hundreds of industry ...

The government has identified life sciences as one of the sectors with the highest potential for growth in the UK and plans to make it a key pillar of its upcoming industry strategy. The ...

The market has been harsh on most growth stocks this year, owing primarily to tariff-related recession fears. In a volatile ...

Sanofi is set to acquire DR-0201 from Dren Bio for up to $1.9 billion, aiming to expand its autoimmune disease pipeline with ...

February saw several changes on boards at biotechs, bringing a diverse wealth of experience to support these companies. Read ...

French pharma major Sanofi (Euronext: SAN) today revealed it has entered into a definitive agreement with privately-held US biotech Dren Bio, to acquire the latter’s DR-0201, a targeted bispecific ...

US pharma major Johnson & Johnson (NYSE: JNJ) has won US approval for Tremfya (guselkumab) in the treatment of adults with ...

The trispecific antibody market is rapidly advancing, with 50+ candidates in clinical trials and first approvals expected by 2028. These next-gen immunotherapies target three distinct antigens, ...